260 related articles for article (PubMed ID: 35669431)
1. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
Front Oncol; 2022; 12():867658. PubMed ID: 35669431
[TBL] [Abstract][Full Text] [Related]
2. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
4. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
5. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
Front Immunol; 2022; 13():809971. PubMed ID: 35185898
[TBL] [Abstract][Full Text] [Related]
6. The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer.
Liu J; Li J; Luo F; Wu S; Li B; Liu K
Curr Oncol; 2023 Oct; 30(11):9647-9659. PubMed ID: 37999119
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
Yang L; Liu S; He W; Xiong Z; Xia L
BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
[TBL] [Abstract][Full Text] [Related]
9. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
10. CD169
Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
[TBL] [Abstract][Full Text] [Related]
11. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
[TBL] [Abstract][Full Text] [Related]
12. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
13. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
[TBL] [Abstract][Full Text] [Related]
14. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
[TBL] [Abstract][Full Text] [Related]
16. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
[No Abstract] [Full Text] [Related]
18. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
19. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
Jin Z; Sinicrope FA
J Clin Oncol; 2022 Aug; 40(24):2735-2750. PubMed ID: 35649217
[TBL] [Abstract][Full Text] [Related]
20. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer.
Hestetun KE; Rosenlund NB; Stanisavljević L; Dahl O; Myklebust MP
Front Oncol; 2022; 12():853545. PubMed ID: 36110945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
